Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

Raymund R. Razonable; John C. O’Horo; Sara N. Hanson; Richard F. Arndt; Leigh L. Speicher; Teresa A. Seville; Scott T. Hall; Marsha L. Pike; Alexander Heyliger; Jennifer J. Larsen; Ravindra Ganesh; Sidna M. Tulledge-Scheitel

doi:10.1093/infdis/jiac346

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

Raymund R. Razonable, John C. O’Horo, Sara N. Hanson, Richard F. Arndt, Leigh L. Speicher, Teresa A. Seville, Scott T. Hall, Marsha L. Pike, Alexander Heyliger, Jennifer J. Larsen, Ravindra Ganesh, Sidna M. Tulledge-Scheitel

Research output: Contribution to journal › Article › peer-review

Abstract

The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of coronavirus disease 2019 (COVID-19) among older patients, immunosuppressed patients, and those with multiple comorbid conditions. Despite its use in patients with multiple comorbid conditions, the rate of progression to severe disease after bebtelovimab (1.4% [95% confidence interval, 1.2%–1.7%]) was not significantly different from that for nirmatrelvir-ritonavir treatment (1.2% [.8%–1.5%]). Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants.

Original language	English (US)
Pages (from-to)	1683-1687
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	226
Issue number	10
DOIs	https://doi.org/10.1093/infdis/jiac346
State	Published - Nov 15 2022

Keywords

COVID-19
Paxlovid
SARS-CoV-2
bebtelovimab
hospitalization
monoclonal antibodies
nirmatrelvir
ritonavir

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/jiac346

Fingerprint

Dive into the research topics of 'Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch'. Together they form a unique fingerprint.

Cite this

Razonable, R. R., O’Horo, J. C., Hanson, S. N., Arndt, R. F., Speicher, L. L., Seville, T. A., Hall, S. T., Pike, M. L., Heyliger, A., Larsen, J. J., Ganesh, R., & Tulledge-Scheitel, S. M. (2022). Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch. Journal of Infectious Diseases, 226(10), 1683-1687. https://doi.org/10.1093/infdis/jiac346

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch. / Razonable, Raymund R.; O’Horo, John C.; Hanson, Sara N. et al.
In: Journal of Infectious Diseases, Vol. 226, No. 10, 15.11.2022, p. 1683-1687.

Research output: Contribution to journal › Article › peer-review

Razonable, RR, O’Horo, JC, Hanson, SN, Arndt, RF, Speicher, LL, Seville, TA, Hall, ST, Pike, ML, Heyliger, A, Larsen, JJ, Ganesh, R & Tulledge-Scheitel, SM 2022, 'Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch', Journal of Infectious Diseases, vol. 226, no. 10, pp. 1683-1687. https://doi.org/10.1093/infdis/jiac346

Razonable RR, O’Horo JC, Hanson SN, Arndt RF, Speicher LL, Seville TA et al. Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch. Journal of Infectious Diseases. 2022 Nov 15;226(10):1683-1687. doi: 10.1093/infdis/jiac346

@article{ff744164e8c04d0992334c84ca30c892,

title = "Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch",

abstract = "The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of coronavirus disease 2019 (COVID-19) among older patients, immunosuppressed patients, and those with multiple comorbid conditions. Despite its use in patients with multiple comorbid conditions, the rate of progression to severe disease after bebtelovimab (1.4% [95% confidence interval, 1.2%–1.7%]) was not significantly different from that for nirmatrelvir-ritonavir treatment (1.2% [.8%–1.5%]). Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants.",

keywords = "COVID-19, Paxlovid, SARS-CoV-2, bebtelovimab, hospitalization, monoclonal antibodies, nirmatrelvir, ritonavir",

author = "Razonable, {Raymund R.} and O{\textquoteright}Horo, {John C.} and Hanson, {Sara N.} and Arndt, {Richard F.} and Speicher, {Leigh L.} and Seville, {Teresa A.} and Hall, {Scott T.} and Pike, {Marsha L.} and Alexander Heyliger and Larsen, {Jennifer J.} and Ravindra Ganesh and Tulledge-Scheitel, {Sidna M.}",

year = "2022",

month = nov,

day = "15",

doi = "10.1093/infdis/jiac346",

language = "English (US)",

volume = "226",

pages = "1683--1687",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

AU - Razonable, Raymund R.

AU - O’Horo, John C.

AU - Hanson, Sara N.

AU - Arndt, Richard F.

AU - Speicher, Leigh L.

AU - Seville, Teresa A.

AU - Hall, Scott T.

AU - Pike, Marsha L.

AU - Heyliger, Alexander

AU - Larsen, Jennifer J.

AU - Ganesh, Ravindra

AU - Tulledge-Scheitel, Sidna M.

PY - 2022/11/15

Y1 - 2022/11/15

N2 - The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of coronavirus disease 2019 (COVID-19) among older patients, immunosuppressed patients, and those with multiple comorbid conditions. Despite its use in patients with multiple comorbid conditions, the rate of progression to severe disease after bebtelovimab (1.4% [95% confidence interval, 1.2%–1.7%]) was not significantly different from that for nirmatrelvir-ritonavir treatment (1.2% [.8%–1.5%]). Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants.

AB - The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of coronavirus disease 2019 (COVID-19) among older patients, immunosuppressed patients, and those with multiple comorbid conditions. Despite its use in patients with multiple comorbid conditions, the rate of progression to severe disease after bebtelovimab (1.4% [95% confidence interval, 1.2%–1.7%]) was not significantly different from that for nirmatrelvir-ritonavir treatment (1.2% [.8%–1.5%]). Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants.

KW - COVID-19

KW - Paxlovid

KW - SARS-CoV-2

KW - bebtelovimab

KW - hospitalization

KW - monoclonal antibodies

KW - nirmatrelvir

KW - ritonavir

UR - http://www.scopus.com/inward/record.url?scp=85141891972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141891972&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiac346

DO - 10.1093/infdis/jiac346

M3 - Article

C2 - 36124696

AN - SCOPUS:85141891972

SN - 0022-1899

VL - 226

SP - 1683

EP - 1687

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 10

ER -

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this